Article
Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.
Antimicrobial agents and chemotherapy - 1 Apr 2003
Colonno Richard J, Thiry Alexandra, Limoli Kay, Parkin Neil
Abstract excerpt
To evaluate the cross-resistance profile of the human immunodeficiency virus type 1 protease inhibitor (PI) atazanavir (BMS-232632), a panel of 551 clinical isolates exhibiting a wide array of PI resistance profiles and a variety of genotypic patterns were assayed for susceptibility to atazanavir and six other PIs: amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir. In general, reductions in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.